Form 4: Intra-Cellular Therapies CEO Sharon Mates Reports Stock Transactions

Sharon Mates, Chairman and CEO of Intra-Cellular Therapies, reports the vesting and subsequent tax withholding of shares related to restricted stock units.

Summary

• On March 1, 2025, Sharon Mates, Chairman and CEO of Intra-Cellular Therapies, reported transactions involving the company's common stock.
• 34,969 restricted stock units vested and converted into common stock on a one-for-one basis.
• 16,978 shares were withheld by the issuer to satisfy tax withholding obligations at a price of $128.2 per share.
• Following these transactions, Mates directly owns 1,103,934 shares of common stock and 69,940 restricted stock units.
• The restricted stock units were granted on March 1, 2024, and vest in three equal annual installments beginning on the first anniversary of the grant date.

Sentiment

Score: 5

Explanation: This is a routine filing related to executive compensation and stock ownership, with no inherently positive or negative implications for the company's overall prospects.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders, like the CEO, trade their company's stock; this provides transparency to investors.

Stakeholder Impact

• The transactions have a minor impact on the total number of outstanding shares.
• The tax withholding benefits the government.

Key Dates